ATG4B Protein — Autophagy Related 4B

ATG4B Protein — Autophagy Related 4B

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATG4B Protein — Autophagy Related 4B</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td><strong>Autophagy-related protein 4B</strong></td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[ATG4B](/genes/atg4b)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y4P1" target="_blank">Q9Y4P1</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Cysteine protease fold, N-terminal regulatory domain</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Autophagosome membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>ATG4 family (cysteine proteases)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/macular-degeneration" style="color:#ef9a9a">Macular Degeneration</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">109 edges</a></td>
</tr>
</table>

ATG4B Protein — Autophagy Related 4B

Introduction

ATG4B Protein — Autophagy Related 4B

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ATG4B Protein — Autophagy Related 4B</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td><strong>Autophagy-related protein 4B</strong></td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[ATG4B](/genes/atg4b)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9Y4P1" target="_blank">Q9Y4P1</a></td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>52 kDa</td>
</tr>
<tr>
<td class="label">Structure</td>
<td>Cysteine protease fold, N-terminal regulatory domain</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Autophagosome membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>ATG4 family (cysteine proteases)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/macular-degeneration" style="color:#ef9a9a">Macular Degeneration</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">109 edges</a></td>
</tr>
</table>

ATG4B Protein — Autophagy Related 4B

Introduction

ATG4B (Autophagy-related protein 4B) is a cysteine protease encoded by the [ATG4B gene](/genes/atg4b) that plays a critical role in the autophagy pathway. As the master regulator of LC3/GABARAP processing, ATG4B is essential for autophagosome biogenesis and the degradation of damaged proteins and organelles. This function is particularly important in post-mitotic [neurons](/entities/neurons), which cannot dilute toxic protein aggregates through cell division and rely heavily on autophagy for proteostasis. UniProt ID: [Q9Y4P1](https://www.uniprot.org/uniprot/Q9Y4P1).

Overview

ATG4B is a 393-amino acid cysteine protease that catalyzes the proteolytic processing of LC3 (Microtubule-associated protein 1A/1B-light chain 3) and GABARAP (GABA receptor-associated protein) family members. Unlike other ATG4 isoforms (ATG4A, ATG4C, ATG4D), ATG4B exhibits broad substrate specificity and can process all known ATG8 homologs, making it the predominant functional protease in basal autophagy [1](https://pubmed.ncbi.nlm.nih.gov/19837670/).

Structure

Enzyme Architecture

ATG4B possesses a bipartite domain structure essential for its function:

• N-terminal regulatory domain (residues 1-150): Contains the LC3-interacting region (LIR) docking site and substrate recognition motifs. This domain regulates access to the catalytic site and determines substrate specificity.
• C-terminal protease domain (residues 151-393): Features the conserved cysteine protease fold with the catalytic triad:
• Cys74: Nucleophilic residue in the active site
• His278: Catalytic histidine
• Asp275: Catalytic aspartate

Catalytic Mechanism

The protease activity follows a classic cysteine protease mechanism:

Structural Features

• Prodomain: Contains an inhibitory region that auto-regulates protease activity
• LIR motif: Enables binding to LC3 on autophagosomes
• Phosphorylation sites: Ser34, Ser398 regulate activity via post-translational modification [2](https://pubmed.ncbi.nlm.nih.gov/23684573/)

Normal Function

LC3 Processing: The Critical Gatekeeper

ATG4B catalyzes three essential reactions in the autophagy cycle:

1. Proteolytic Activation (Priming)

ATG4B cleaves the C-terminal arginine of pro-LC3, exposing a conserved glycine residue. This is the essential first step for LC3 lipidation.

2. Lipid Conjugation (Activation)

Though ATG4B doesn't catalyze this reaction (performed by ATG3/ATG7), the primed LC3-I can be conjugated to phosphatidylethanolamine (PE) in the autophagosome membrane.

3. Delipidation (Recycling)

ATG4B can reverse the lipidation, cleaving LC3-II from the autophagosome membrane to recycle LC3 for new autophagosome formation. This function is crucial for maintaining the ATG8 pool during sustained autophagy [3](https://pubmed.ncbi.nlm.nih.gov/21454547/).

Substrate Specificity

ATG4B processes the entire ATG8 family:

• LC3A, LC3B, LC3C (MAP1LC3 family)
• GABARAP, GABARAPL1, GABARAPL2 (GABARAP family)

Role in Neurodegenerative Diseases

Alzheimer's Disease

ATG4B dysfunction contributes to Alzheimer's disease pathogenesis through multiple mechanisms:

Amyloid-β Metabolism

• Impaired ATG4B activity reduces autophagic clearance of [amyloid precursor protein](/entities/app-protein) (APP) processing intermediates
• Autophagosomes accumulate in AD neurons, indicating defective maturation rather than initiation failure [4](https://pubmed.ncbi.nlm.nih.gov/20303854/)
• Reduced LC3-II levels in AD brain tissue correlate with disease severity

Tau Pathology

• Autophagy impairment prevents clearance of hyperphosphorylated [tau](/proteins/tau) oligomers
• ATG4B activity decline contributes to [tau](/proteins/tau) aggregate formation
• Therapeutic enhancement of ATG4B may reduce tau burden [5](https://pubmed.ncbi.nlm.nih.gov/25053646/)

Synaptic Dysfunction

• Autophagy is essential for synaptic protein turnover
• ATG4B deficits lead to synaptic vesicle protein accumulation
• Cognitive decline correlates with autophagy dysfunction in AD models

Parkinson's Disease

α-Synuclein Clearance

• Autophagosomes directly engulf cytosolic α-synuclein
• ATG4B processes LC3 required for α-synuclein-containing autophagosomes
• Loss-of-function mutations or decreased ATG4B activity contribute to Lewy body formation [6](https://pubmed.ncbi.nlm.nih.gov/22440595/)

Mitophagy and Dopaminergic Neurons

• Dopaminergic neurons are particularly dependent on mitophagy for mitochondrial quality control
• PINK1/Parkin-mediated mitophagy requires ATG8 family proteins
• ATG4B deficiency exacerbates mitochondrial dysfunction in PD models [7](https://pubmed.ncbi.nlm.nih.gov/25843709/)

LRRK2 Pathogenesis

• [LRRK2](/entities/lrrk2) mutations (G2019S) impair autophagy through ATG4B dysregulation
• LRRK2 kinase activity affects LC3 lipidation
• ATG4B activators may counteract LRRK2-mediated autophagy defects

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Vulnerability

• Large axonal arbors requiring constant protein turnover
• High mitochondrial density and energy demands
• Limited regenerative capacity

Protein Aggregate Clearance

• ALS-linked mutations (SOD1, [TDP-43](/proteins/tdp-43), FUS, C9orf72) cause toxic protein aggregation
• ATG4B insufficiency leads to incomplete autophagic clearance
• Aggresomes overwhelm the proteostatic machinery [8](https://pubmed.ncbi.nlm.nih.gov/24389470/)

ER Stress

• ATG4B dysfunction contributes to ER stress in ALS
• Impaired autophagy disrupts protein quality control
• [Unfolded protein response](/entities/unfolded-protein-response) (UPR) activation in motor neurons

Huntington's Disease

Mutant Huntingtin Clearance

• ATG4B processes LC3 required for [huntingtin](genes/htt) aggregate clearance
• Autophagy induction reduces mutant [huntingtin](/proteins/huntingtin) toxicity in models
• ATG4B activity correlates with disease progression [9](https://pubmed.ncbi.nlm.nih.gov/21454547/)

Therapeutic Targeting

ATG4B Activators

Several strategies are being explored to enhance ATG4B activity:

Small Molecule Activators

• Flavonoids: Quercetin and kaempferol show ATG4B activation
• Natural compounds: Ginsenoside Rg3 enhances ATG4B activity
• Synthetic activators: High-throughput screens identify novel small molecules [10](https://pubmed.ncbi.nlm.nih.gov/26225733/)

Mechanism of Action

• Allosteric binding to enhance catalytic efficiency
• Reducing oxidative stress-mediated inhibition
• Increasing ATG4B expression through Nrf2 pathway

Gene Therapy Approaches

AAV-Mediated Delivery

• Adeno-associated virus (AAV) vectors can deliver ATG4B to neurons
• Neuron-specific promoters ensure targeted expression
• Preclinical studies show promise in models of neurodegeneration [11](https://pubmed.ncbi.nlm.nih.gov/30026540/)

CRISPR Activation

• dCas9-Sam system enhances ATG4B transcription
• Temporal control allows adjustable expression levels
• Combination approaches with other autophagy genes

Combination Strategies

Autophagy Enhancement

• ATG4B activators combined with [mTOR](/entities/mtor) inhibitors (rapamycin, everolimus)
• Synergistic effect on autophagic flux
• Lower doses reduce off-target effects

Proteostasis Network

• Combined autophagy enhancement and ubiquitin-proteasome activation
• Addresses both aggregate clearance pathways
• Therapeutic potential in multiple neurodegenerative diseases

Research Status and Future Directions

Current Understanding

• ATG4B is the rate-limiting protease in LC3 processing
• Activity declines with age in neurons
• Genetic variants may confer susceptibility to neurodegeneration

Knowledge Gaps

• Neuron-specific regulation of ATG4B
• Interaction with disease-causing mutations
• Optimal delivery methods for therapeutic activation

Clinical Translation

• No ATG4B-targeted therapies in clinical trials yet
• Biomarkers for monitoring autophagy enhancement needed
• Patient selection based on genetic and biomarker profiles

Key Publications

See Also

• [ATG4B Gene](/genes/atg4b) — Gene page
• [Autophagy](/entities/autophagy) — Autophagy pathway
• [LC3 Protein](/proteins/lc3-protein) — LC3/ATG8
• [Alzheimer's Disease](/diseases/alzheimers-disease) — AD overview
• [Parkinson's Disease](/diseases/parkinsons-disease) — PD overview
• [ALS](/diseases/amyotrophic-lateral-sclerosis) — ALS overview

Background

The study of Atg4B Protein — Autophagy Related 4B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References